Share with friends and circles of friends with wechat scanning QR code < / P > < p > on August 5, Zhixiang biology recently announced the completion of round C financing, with a financing amount of more than 500 million yuan. This round of financing was jointly led by Gaorong capital and Qingsong capital, followed by Fuhui venture capital, Xinyin investment Beijing, Founder Securities Investment, Wenhua Haihui, etc., and Sanjiang capital acted as the exclusive financial adviser

it is reported that this round of financing will be used for rapid expansion of commercial production capacity, comprehensive upgrading of technology platform, international business strategic layout and expansion of talent team

Zhixiang bio was founded in April, 2018, focusing on the development of macromolecular biopharmaceutical processes and large-scale commercial production of cdmo. Zhixiang biology has seven cdmo technology platforms, including GMP production platform, ADC platform, multiple cultivation platform, independent cell construction platform, drug analysis platform, virus safety detection platform, and preparation development platform. The company has production bases in Suzhou Xiangcheng high tech Zone, industrial park and Changshu high tech Zone respectively. At present, all bases have started the expansion project of flexible production lines, and the total planned production capacity will reach 220000 liters in 2023

at present, Zhixiang biological service category covers monoclonal antibody, double antibody, multi antibody, fusion protein, vaccine, ADC, etc., and it is also one of the few domestic enterprises that can produce ADC drugs

in the future, Zhixiang biology will continue to cultivate sub circuits, continuously improve the size and overall production capacity of the enterprise, further deepen the moat of the enterprise with differentiated services, and enhance the international competitiveness of the enterprise

Li Zhi, CEO of Zhixiang biology, said: "We are committed to accelerating the listing of more new drugs, and have accumulated rich experience in the process of practice to find the optimal solution path for the whole process service from ind to bla. We will also maintain the vision and values of long-term development, help customers in decision-making difficulties, prepare for long-term development, and adhere to the path of sustainable management. We will continue to focus on the field of cdmo and explore infinite possibilities. Let Zhixiang biology become the leader of the global cdmo field Leading enterprises in order to benefit more patients. " (one orange)